Pi Health, a clinical research and health technology startup with a focus on oncology located in Cambridge, Massachusetts, has raised approximately $30 million in Series A funding.
The company is dedicated to revolutionizing worldwide access to new medications and clinical trials.
AlleyCorp and Obvious Ventures led the round, with additional funding from global oncology experts and Invus Capital.
The money will be used by the business to grow its alliances with international trial sites and life sciences firms as well as to advance the development of its FICS technology.
Pi Health is an oncology clinical trial and research technology firm that was founded in 2021 and is directed by CEO Geoffrey Kim, M.D. Pi Health’s mission is to enable life science companies to create treatments quickly and serve a variety of patient populations using their clinical trial platform.
Its single-solution software, known as FICS (short for “Front-End Interoperable Capture Software”), links life science sponsors and trial sites and automates manual procedures for quicker, better-quality data gathering.
It also gathers “finish-line data” right away. In addition to a new cancer hospital in Hyderabad, India, the group has connections with oncology centers in the US, Brazil, Australia, and India’s health systems.
About Pi Health
Pi Health is a technology and clinical trial oncology firm dedicated to revolutionizing worldwide access to cutting-edge medications. Using their clinical trial platform, the group, which was founded in 2021, aims to enable life science businesses to develop medications more quickly and to cover a wider range of patient populations. Along with a new cancer hospital in Hyderabad, India, the organization’s health system partnerships include oncology centers in the US, Brazil, Australia, and India. These partnerships embody Pi Health’s purpose to provide contemporary, efficient, and equitable trials to populations worldwide.
